35 studies found for:    rigosertib
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Conditions: Myelodysplastic Syndrome;   MDS;   Trisomy 8
Intervention: Drug: rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: November 2015
2 Completed Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
Condition: Healthy
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: August 2015
3 Completed Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Condition: Solid Tumor
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: December 2015
4 Active, not recruiting Oral Rigosertib in Combination With Azacitidine
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions: Drug: oral rigosertib;   Drug: Azacitidine
Phases: Phase 1 / Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: May 2017
5 Not yet recruiting A Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Conditions: Leukemia;   Myelofibrosis;   Anemia;   Splenomegaly
Interventions: Drug: Rigosertib;   Behavioral: Questionnaire
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Onconova Therapeutics, Inc.
Study Completion:
6 Completed Oral Rigosertib for Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma;   Anal Squamous Cell Carcinoma;   Lung Squamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Penile Squamous Cell Carcinoma
Intervention: Drug: rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: April 2016
7 Active, not recruiting Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Condition: Myelodysplastic Syndromes
Intervention: Drug: Oral rigosertib
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: March 2017
8 Suspended Three Dosing Schedules of Oral Rigosertib in MDS Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: rigosertib
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: October 2017
9 Completed Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Myeloproliferative Disease;   Chronic Myeloid Leukemia
Intervention: Drug: rigosertib
Phases: Phase 1 / Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: June 2014
10 Completed Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
Conditions: Advanced Cancer;   Solid Tumors;   Cancer;   Neoplasms
Intervention: Drug: rigosertib sodium
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: January 2012
11 Completed Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Conditions: Head and Neck Neoplasms;   Carcinoma, Squamous Cell
Interventions: Drug: oral rigosertib;   Drug: cisplatin;   Radiation: Radiotherapy
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: January 2015
12 Recruiting Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Conditions: Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions: Drug: rigosertib;   Drug: Any approved or standard-of-care therapy
Phase: Phase 3
Sponsor: Onconova Therapeutics, Inc.
Study Completion: September 2018
13 Active, not recruiting Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Conditions: Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention: Drug: rigosertib sodium
Phase: Phase 3
Sponsor: Onconova Therapeutics, Inc.
Study Completion: June 2017
14 Completed Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
Conditions: Solid Tumors;   Advanced Cancer;   Cancer;   Neoplasms
Intervention: Drug: rigosertib sodium
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: November 2011
15 Completed Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: December 2015
16 Completed Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
Phase: Phase 2
Sponsor: Onconova Therapeutics, Inc.
Study Completion: November 2013
17 Completed Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Conditions: Malignant Neoplasmas;   Solid Tumors
Interventions: Drug: gemcitabine;   Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: September 2011
18 Completed Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: December 2015
19 Completed Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Condition: Advanced Solid Tumors
Interventions: Drug: ON 01910.Na and irinotecan;   Drug: ON 01910.Na and oxaliplatin
Phase: Phase 1
Sponsor: Onconova Therapeutics, Inc.
Study Completion: July 2011
20 Completed Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na;   Drug: Gemcitabine
Phase: Phase 3
Sponsor/Collaborators: Onconova Therapeutics, Inc.;   Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Study Completion: December 2015

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years